Table 1.
Summary of the potential drug candidates selected from recent literature on COVID-19. Drugs are categorized on the basis of their mode of actions.
| Category | Drug candidate(s) |
|---|---|
| Analgesic | Diperodon, Phenazopyridine, Tetrandrine |
| Anti-bacterial | Dihydrocelastryl diacetate, Monensin sodium, Oligomycin, Salinomycin sodium, Valinomycin |
| Anti-depressant | Desipramine |
| Anti-fungal | Antimycin A, Exalamide, Phenylmercuric acetate |
| Anti-helminthic | Pyrviniumpamoate, Ivermectin |
| Anti-histamine | Chloropyramine |
| Anti-hypertensive | Alprenolol, Berbamine, Carvedilol, Doxazosinmesylate, Irbesartan, Propranolol |
| Anti-infective | Cetylpyridinium chloride, Camphor |
| Anti-inflammatory | Colchicine, Emodin, Mesalazine |
| Anti-malarial | Chloroquine, Conessine, Hydroxychloroquine, Quinacrine |
| Anti-neoplastic | Dactinomycin, Hydroxychalcone, Lycorine, Mercaptopurine, Mycophenolate mofetil, Mycophenolic acid, Pristimerin, Toremifene |
| Anti-Parkinsonian | Harmine |
| Anti-protozoal | Nitazoxanide |
| Anti-psychotic | Promazine |
| Anti-viral | Acyclovir, Favipiravir, Ganciclovir, Lopinavir, Oseltamivir, Penciclovir, Remdesivir, Ribavirin, Ritonavir, Tilorone |
| Ca2+ channel blocker | Loperamide |
| Diuretic | Eplerenone |
| Estrogen steroid | Equilin |
| Hormone | Melatonin |
| IL-6 inhibitor | Tocilizumab |
| Immunosuppresants | Sirolimus |
| Muscle relaxant | Papaverine, Zoxazolamine |
| PAF inhibitor | Ticlopidine |
| Protein synthesis blocker | Cycloheximide, Emetine |
| Selective serotonin reuptake inhibitor | Paroxetine |
| Steroid hormone | Oxymetholone |
| Serine protease inhibitor | Nafamostat |